Brief: Jyong Biotech Announces Completion Of Primary Endpoint Statistical Analysis For Phase Ii Clinical Trial Of Mcs-8 With Positive Outcomes
20/11/2025 13:57
Jyong Biotech Ltd MENS.O: JYONG BIOTECH ANNOUNCES COMPLETION OF PRIMARY ENDPOINT STATISTICAL ANALYSIS FOR PHASE II CLINICAL TRIAL OF MCS-8 WITH POSITIVE OUTCOMES JYONG BIOTECH LTD: MCS-8 REMAINS INVESTIGATIONAL NEW DRUG CANDIDATE & HAS NOT BEEN APPROVED FOR COMMERCIAL USE IN ANY JURISDICTION Source text: ID:nGNX4nNYZZ Further company coverage: MENS.O